Silo Pharma shares are trading lower after the company completed a pre-investigational new drug meeting with the FDA for SPOC-15, an intranasal prophylactic treatment for PTST and stress-induced anxiety disorder.
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma's shares declined following the completion of a pre-investigational new drug meeting with the FDA for their SPOC-15 treatment, aimed at PTST and stress-induced anxiety disorder.
September 10, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Silo Pharma's stock is trading lower after a meeting with the FDA regarding their SPOC-15 treatment. This suggests investor uncertainty or disappointment with the regulatory progress.
The decline in Silo Pharma's stock price indicates a negative market reaction to the FDA meeting. This could be due to investor concerns about the regulatory hurdles or the timeline for SPOC-15's development. The meeting's outcome may not have met investor expectations, leading to a sell-off.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100